Achalasia

Achalasia is a primary esophageal motility disorder characterized by the failure of the lower esophageal sphincter (LES) to relax during swallowing and the absence of organized esophageal peristalsis. This leads to impaired bolus transit, progressive functional obstruction, and esophageal dilation.

The primary cause of achalasia is idiopathic. Pathogenesis involves an autoimmune-mediated inflammatory response triggered by environmental or viral factors (e.g., Herpes Simplex Virus 1) in genetically susceptible individuals (associated with HLA class II antigens). Secondary achalasia (pseudoachalasia) is caused by malignancy (e.g., gastric or lung adenocarcinoma) or Chagas disease (Trypanosoma cruzi).

Achalasia results from the selective loss of inhibitory, nitric oxide- and vasoactive intestinal peptide (VIP)-producing nitrergic ganglion cells in the myenteric (Auerbach's) plexus of the esophageal wall. The preservation of excitatory cholinergic neurons leads to unopposed stimulation, causing basal LES hypertension and incomplete relaxation. Over time, progressive degeneration of the esophageal body leads to aperistalsis and dilation.

• Prevalence: ~10 cases per 100,000 individuals.
• Incidence: ~1 to 2 cases per 100,000 annually.
• Age Distribution: Bimodal distribution peaks at ages 30–40 and 60–7

• Gender: Affects males and females equally.

Autoimmune predisposition (HLA-DQB106:02 allele)

• Chronic viral infections (HSV-1)


• Geographical exposure to Chagas disease (Central/South America)

Physical examination is usually normal in early-to-moderate disease. Advanced disease may reveal:

• Vital Signs: Tachypnea or fever (if aspiration pneumonia is present).


• Inspection: Temporal wasting and cachexia; dry mucous membranes.


• Auscultation: Coarse crackles or diminished breath sounds at pulmonary bases.

• A. Clinical Assessment: Validated symptom scoring using the Eckardt Score.
• B. Laboratory Testing: Evaluates nutritional status and excludes infectious etiologies.
• C. Imaging Studies: Barium esophagram to assess structural anomalies.
• D. Functional Tests: High-Resolution Manometry (HRM) is the diagnostic gold standard.
• E. Biopsy Findings: Done via endoscopy to rule out pseudoachalasia. Histology reveals chronic inflammatory infiltrates and loss of myenteric ganglion cells.
• F. Genetic Testing: Not routinely recommended unless syndromic association is suspected (e.g., Triple A/Allgrove Syndrome).
• G. Differential Diagnosis: Differentiating from malignant obstruction and gastroesophageal reflux disease (GERD).

Chagas Serology

• Type: Blood Test (ELISA/IFA)

• Expected Findings: Negative.


• Interpretation: Positive findings confirm Chagasic pseudoachalasia. Complete Metabolic Panel (CMP)


• Type: Blood Test


• Purpose: Assess nutritional status and electrolyte balance.


• Expected Findings: Hypoalbuminemia and electrolyte imbalances in severe cases.


• Interpretation: Identifies malnutrition secondary to chronic dysphagia.

• Barium Esophagram: Retained barium column, esophageal dilation, and classic "bird's beak" tapering at the gastroesophageal junction.
• Upper Endoscopy (EGD): Evaluates mucosa. Findings include retained saliva/undigested food, dilated esophagus, and resistance to scope passage at the LES ("pop" sign). Essential to rule out malignancy.
• High-Resolution Manometry (HRM): Classified via Chicago Classification (v4.0). Typified by an integrated relaxation pressure (IRP) above upper limits of normal, alongside aperistalsis (Type I: classic; Type II: panesophageal compression; Type III: spastic).

• Esophageal Cancer: Diagnosed via abnormal mucosal lesion/mass on endoscopy and confirmed on biopsy.
• GERD: Marked by intact peristalsis, normal LES relaxation on manometry, and positive pH testing.
• Diffuse Esophageal Spasm (DES): Characterized by normal LES relaxation with uncoordinated/hypercontractile peristalsis.

• Aspiration pneumonia
• Megaesophagus (sigmoid esophagus)
• Esophageal squamous cell carcinoma (due to chronic stasis and mucosal inflammation)
• Esophageal perforation (complication of pneumatic dilation)
• Severe malnutrition and cachexia

Treatment provides excellent symptomatic relief (Eckardt score ≤ 3) in over 85–90% of patients undergoing POEM or LHM. However, achalasia is a progressive, incurable condition requiring long-term surveillance.

No primary prevention exists. Secondary prevention focuses on preventing aspiration events and routine endoscopic surveillance for esophageal dysplasia.

The following homeopathic remedies have been historically indicated for symptoms associated with Achalasia. Selection should be based on individualized symptom totality and constitutional assessment.

• Homeopathy by Hadhrat Mirza Tahir Ahmad (r.a.) — Primary clinical reference
• Robin Murphy — Lotus Materia Medica (3rd Edition)
• William Boericke — Pocket Manual of Homœopathic Materia Medica & Repertory
• ICD-10/ICD-11 Classification — World Health Organization
• Harrison's Principles of Internal Medicine (Reference Standard)

This clinical reference profile is compiled from authoritative medical sources for educational purposes. Always verify clinical data with current medical guidelines.

🔬 Lab Report Analyzer (Diagnostic Verification)

Upload your laboratory bloodwork PDF or paste your report text to automatically extract markers, detect units, and identify reference range variances related to Achalasia.